Multi-omics evaluation of peritoneal fluid in gastroesophageal cancer (OMEGCA): protocol for a prospective multicentre cohort study to detect occult peritoneal metastases in patients undergoing curative-intent treatment

Liu, DS; Allan, Z; Tie, J; Hall, K; Lee, MM; Wong, DJ; Wong, SQ; Tebbutt, NC; Watson, DI; Trochsler, M; Mori, K; Winter, N; Martin, S; Ooi, G; Al-Habbal, Y; Ma, R; Clemons, NJ

Author(s): Liu, DS; Allan, Z; Tie, J; Hall, K; Lee, MM; Wong, DJ; Wong, SQ; Tebbutt, NC; Watson, DI; Trochsler, M; Mori, K; Winter, N; Martin, S; Ooi, G; Al-Habbal, Y; Ma, R; Clemons, NJ;
Details: Publication Year 2025,Volume 20,Issue #4,Page e0318615
Journal Title: PLoS One
Publication Type: Protocol
Abstract: INTRODUCTION: Early detection of peritoneal disease, especially micro-metastases, in patients with gastroesophageal adenocarcinoma is critical as it alters therapeutic intent, providing a vital opportunity to personalise treatment. However, our ability to accurately stage the peritoneum is inadequate. Tumour-derived DNA in peritoneal lavage fluid (ptDNA) has been suggested to be more sensitive than current methods to stage the peritoneum. Accordingly, this study will determine whether ptDNA is a biomarker of peritoneal micro-metastasis and evaluate its prognostic value in patients with gastroesophageal adenocarcinoma undergoing curative-intent treatment. METHODS AND ANALYSIS: This will be an Australian multi-centre prospective observational cohort study enrolling patients undergoing routine staging laparoscopy and subsequent curative-intent treatment (either upfront surgery or perioperative chemo-/radiotherapy and surgery) for gastric and gastroesophageal junction adenocarcinoma. Tumour biopsies, blood and peritoneal lavage fluid will be collected at the time of staging laparoscopy for all patients. A subset of patients will have blood and peritoneal fluid collected at the time of surgical resection, and blood collected at the first post-operative clinic. These biospecimens will undergo genomic and methylomic analysis to detect tumour DNA. ptDNA status will be correlated to disease free survival, peritoneal-specific event free survival, overall survival, sites of treatment failure, histopathological features, and peritoneal lavage cytology status. REGISTRATION: This study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12624000451505p).
Publisher: PLOS
Keywords: Humans; *Stomach Neoplasms/pathology/genetics/therapy; Prospective Studies; *Esophageal Neoplasms/pathology/genetics/therapy; *Ascitic Fluid/metabolism; *Peritoneal Neoplasms/secondary/diagnosis/genetics; *Adenocarcinoma/pathology/genetics/therapy; Biomarkers, Tumor/genetics; Female; Male; Esophagogastric Junction/pathology; DNA, Neoplasm/genetics; Prognosis; Australia; Multiomics
Department(s): Surgical Oncology; Laboratory Research; Medical Oncology
Publisher's Version: https://doi.org/10.1371/journal.pone.0318615
Open Access at Publisher's Site: https://doi.org/10.1371/journal.pone.0318615
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-05-13 07:45:04

Last Modified: 2025-05-13 07:45:21